Privo Technologies, Inc. Announces Publication in Nature Communications | Panda Anku

PEABODY, Mass., August 24, 2022 /PRNewswire/ — Privo Technologies, Inc. (“Privo”), a phase 3 clinical-stage biopharmaceutical company that has designed and developed a nanotechnology drug delivery platform to safely deliver highly potent drugs locally and regionally, announced nature communication published the results of the assessment of efficacy and safety data collected with PRV111 in animal models of oral cancer and in clinical trials in patients with squamous cell carcinoma of the oral cavity (OCSCC).

The article entitled “A nanoengineered topical transmucosal cisplatin delivery system induces an anti-tumor response in animal models and patients with oral cancer” describes the observed therapeutic benefit of topical administration of high concentrations of cisplatin via the PRV platform to the tumor and regional lymph nodes while avoiding systemic circulation. “We are very pleased to publish our work in a prestigious journal such as Nature Communications. These data underscore the promise of a targeted and local chemotherapy regimen and confirm the superior mechanism and design of the PRV platform and its lead derivative, PRV111. These data serve as a critical milestone for entering a Phase 3 clinical trial for patients with carcinoma in situ of the oral cavity, as well as a springboard for exploring the use of the platform in other mucosal cancers such as lung, cervical, vaginal and rectal, and anal cancer,” said Maniye Goldberg, PhD, Founder and CEO of Privo. dr Goldberg is the first author of the article, written in collaboration with Dr. Nishant AgrawalMD FACS, and Dr. Evgeny Izumchenko, PhD, at the University of Chicago, Department of Surgery and Department of Medicine respectively. dr Goldberg, Dr. Agrawal and Dr. Izumchenko are the corresponding authors.

“The data from this document represents a validation of our platform for nanoencapsulation of high-potency drugs while providing controlled delivery and release. Privo is pleased to add to the growing body of scientific evidence demonstrating that encapsulation for the local delivery of highly toxic chemotherapy and other drug classes can unlock therapeutic benefits and disrupt the targeted drug delivery industry both topically and intraoperatively,” said Dr Goldberg, “We are grateful to our clinical centers and their investigative teams for their participation in this study, and of course we are indebted to our patients and the oral cancer community for their support of our technology.” Enrollment sites included the UT Health Science Center School of Dentistry and Baylor College of Medicine in Houston, Texas; University of Cincinnati Cancer Institute in Cincinnati, OH; Advanced ENT and Allergy in Louisville, Kentucky; Ben Taub Hospital and Memorial Hermann Hospital in Houston, Texas.

“Treatment for oral cancer can involve life-changing surgeries that can impact function. The data presented on Privo’s PRV111 is an important step in the approval process of a transformative product that has the potential to change the standard of care,” he told DR. Nishant Agrawal. dr Agrawal is Chief Physician of Otolaryngology-Head and Neck Surgery and Co-Director of Head and Neck Surgical Oncology at University of Chicago.

The full article is available in print and digital format and can be viewed via the following link: (

nature communication is a peer-reviewed, open access, multidisciplinary journal dedicated to the publication of quality research in all areas of biology, health, physics, chemistry and earth sciences.

About Privo Technologies, Inc.

Privo Technologies, Inc. (“Privo”) is a Phase 3, clinical-stage biopharmaceutical company committed to the development of innovative therapeutics aimed at eliminating and preventing cancer from coming back. Privo aims to bring better and more accessible treatment options to diverse patient populations around the world, with the potential to transform the standard of care for solid tumor management. Privo is headquartered in Peabodya suburb of Boston, Mass.

PRV111, Privo’s lead product, has been shown to be effective in patients with head and neck cancer in multiple US hospitals during a Phase I/II clinical safety and efficacy study, dramatically reducing tumor volume without systemic toxicity. For more information about Privo Technologies, Inc., visit

Media contact: [email protected]

SOURCE Privo Technologies


Leave a Comment